Our Commitment to Combating Ebola

Martin Fitchet M.D., Global Head, Global Public Health, Johnson & Johnson

“Our vision is to protect people and communities at risk of Ebola by preventing outbreaks of this devastating disease before they can begin.”

Johnson & Johnson’s Ebola Vaccine

The preventive Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), contains vaccines based on:

- Janssen’s AdVac® technology (Zabdeno®)
- Bavarian Nordic’s MVA-BN® technology (Mvabea®)

Available clinical data indicate that the two-dose regimen induces a robust and durable immune response in adults and children. Data also demonstrate that booster vaccination with Zabdeno®, administered to adults two years after the initial vaccination, induces a strong immune response.11

Our Progress

250,000+ people worldwide vaccinated with at least the first dose

15 Janssen clinical studies

Phase 1, 2, 3 trials show robust and durable antibody response

* indicates studies for which Janssen were collaborators.

European Commission Approval & WHO Prequalification for J&J’s preventive Ebola vaccine

VACCINATION CAMPAIGN

Rwanda, Guinea

PHASE 1 3, 4, 8
UK, US, Uganda, Kenya, Tanzania

PHASE 2 4-19, 45
US, UK, France, Uganda, Côte d’Ivoire, Kenya, Burkina Faso, Tanzania, Mozambique, Nigeria, Guinea*, Liberia*, Sierra Leone*, Mali*, Uganda*, DRC*

PHASE 3 9, 14, 21
DRC*, Sierra Leone, US, Rwanda*, Burkina Faso, France, Kenya, Tanzania, Uganda, United Kingdom
Working in Partnership

Johnson & Johnson has made a significant investment in our Ebola vaccine development program. We are also grateful for development and funding support from:

- Bavarian Nordic A/S
- Biomedical Advanced Research and Development Authority (BARDA)
- Innovative Medicines Initiative (IMI)
- National Institutes of Health (NIH)
- European Union's Horizon 2020 initiative (EU’s Horizon 2020)

Additionally, we acknowledge the support of our many clinical program partners:

- Centre Muraz
- Coalition for Epidemic Preparedness Innovations
- College of Medicine and Allied Health Sciences (University of Sierra Leone)
- Democratic Republic of the Congo Ministry of Public Health
- Emory University's Project San Francisco (Kigali) / Center for Family Health Research - Epicentre
- Grameen Foundation
- Inserm
- Inserm Transfert
- Institut National de Recherche Biomédicale (INRB)
- London School of Hygiene & Tropical Medicine
- Médecins Sans Frontières
- Republic of Rwanda Ministry of Health and Rwanda Biomedical Center
- RindaUbuza
- Sierra Leone Ministry of Health and Sanitation
- Uganda Virus Research Institute
- University of Antwerp
- University of Oxford
- Université de Kinshasa
- Vibalogics GmbH
- Walter Reed Army Institute of Research
- Welcome Trust
- World Health Organization
- World Vision Ireland

...and all the people who participated in the Ebola vaccine clinical trials.

Commitment to Pandemic Preparedness

Johnson & Johnson is one of the few innovative healthcare companies that is actively engaged on pandemic preparedness and response. Through our Janssen Pharmaceutical Companies, we are developing new vaccines and/or treatments to combat infectious diseases, including:

- COVID-19
- Ebola
- Hepatitis B
- HIV
- Influenza
- Tuberculosis
- Dengue


References


Ebolad Timeline

The Ebola virus was first discovered in 1976 near the Ebola River in what is now the Democratic Republic of the Congo (DRC).23 Over the past 45 years, there have been multiple Ebola outbreaks.24 The worst to date was the West African Ebola epidemic, which caused nearly 30,000 cases and more than 11,000 deaths across Guinea, Liberia and Sierra Leone in 2014-2016.25 The largest second-largest Ebola outbreak took place in the DRC in 2018-2020, causing more than 3,000 cases and 2,000 deaths.26 In 2021, new outbreaks were reported in the DRC and Guinea and in 2022, a new outbreak was reported in the DRC.27

2022


2021

Ghana Food and Drugs Authority grants conditional Marketing Authorization to the vaccine regimen, making its first commercial regulatory approval in Africa. To date, more than 260,000 people worldwide have been vaccinated with at least the first dose of J&J’s Ebola vaccine regimen.

2020

WHO prequalifies J&J’s Ebola vaccine regimen. J&J announces it will provide up to 200,000 vaccine regimens to a WHO early access clinical program in West Africa. WHO SAGE recommends the J&J Ebola vaccine regimen for use, both during outbreaks and preventatively, before outbreaks, for first responders.

2019


2018

First long-term clinical data for Ebola vaccine regimen is published in JAMA®. New partnership with BARDA launches to support U.S. licensure of vaccine regimen.

2017

Second-largest Ebola outbreak begins in North Kivu, DRC.

2015


2014


Program Support and Funding

Johnson & Johnson’s investigational Ebola vaccine regimen was developed in a collaborative research program with the NIH and received funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, under Contract Numbers HHSN272201600025C and HHSN272201600001C. Bavarian Nordic has been providing clinical manufacturing support for the Ebola vaccine regimen to Janssen through the Horizon 2020 European Commission’s Innovative Medicines Initiative (IMI), which is supported by the European Commission, provided funding through the IMI Initiative to support a number of companies that are also developing Ebola vaccines to prevent future outbreaks. The Horizon 2020 funds for the Innovative Medicines Initiative (IMI2) and Horizon 2020 funding are being provided by the European Union and its Member States, Switzerland, Iceland, and Norway. Johnson & Johnson is funding the studies and development of the Ebola vaccine regimen. Janssen Biotech, Inc. and Janssen Vaccines & Therapeutics, a member of the Johnson & Johnson family of companies, are the legal manufacturers of the investigational Ebola vaccine regimen.